UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Clinical pharmacokinetics, 2019-10, Vol.58 (10), p.1265-1279

2019

Volltextzugriff (PDF)

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

British journal of clinical pharmacology, 2013-12, Vol.76 (6), p.908-916

2013

Volltextzugriff (PDF)

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.637-645

2016

Volltextzugriff (PDF)

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

Thrombosis and haemostasis, 2010-12, Vol.104 (6), p.1263-1271

2010

Volltextzugriff (PDF)

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

British journal of clinical pharmacology, 2015-05, Vol.79 (5), p.838-846

2015

Volltextzugriff (PDF)

Assessing recovery of spectacled eiders using a Bayesian decision analysis

PloS one, 2021-07, Vol.16 (7), p.e0253895-e0253895

2021

Volltextzugriff (PDF)

Apixaban metabolism and pharmacokinetics after oral administration to humans

Drug metabolism and disposition, 2009-01, Vol.37 (1), p.74-81

2009

Volltextzugriff (PDF)

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

Drug metabolism and disposition, 2010-03, Vol.38 (3), p.448-458

2010

Volltextzugriff (PDF)

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

British journal of clinical pharmacology, 2013-11, Vol.76 (5), p.776-786

2013

Volltextzugriff (PDF)

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban

Clinical pharmacokinetics, 2015-06, Vol.54 (6), p.651-662

2015

Volltextzugriff (PDF)

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

British journal of clinical pharmacology, 2013-02, Vol.75 (2), p.476-487

2013

Volltextzugriff (PDF)

Warming Arctic summers unlikely to increase productivity of shorebirds through renesting

Scientific reports, 2021-07, Vol.11 (1), p.15277-15277, Article 15277

2021

Volltextzugriff (PDF)

Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects

Journal of clinical pharmacology, 2018-07, Vol.58 (7), p.965-971

2018

Volltextzugriff (PDF)

Characterization of efflux transporters involved in distribution and disposition of apixaban

Drug metabolism and disposition, 2013-04, Vol.41 (4), p.827-835

2013

Volltextzugriff (PDF)

Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults

Clinical therapeutics, 2016-07, Vol.38 (7), p.1674-1685.e1

2016

Volltextzugriff (PDF)

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Drugs in R&D, 2021-12, Vol.21 (4), p.375-384

2021

Volltextzugriff (PDF)

Normothermic Regional Perfusion in Controlled Donation After Circulatory Death Liver Transplantation: A Systematic Review and Meta-Analysis

Transplant international, 2024, Vol.37, p.13263

2024

Volltextzugriff (PDF)

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants

Platelets (Edinburgh), 2023-12, Vol.34 (1), p.2222846-2222846

2023

Volltextzugriff (PDF)

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

British journal of clinical pharmacology, 2018-05, Vol.84 (5), p.876-887

2018

Volltextzugriff (PDF)

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2014-04, Vol.14 (2), p.147-154

2014

Volltextzugriff (PDF)

Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model

Arteriosclerosis, thrombosis, and vascular biology, 2017-05, Vol.37 (5), p.942-948

2017

Volltextzugriff (PDF)

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

American journal of cardiovascular drugs : drugs, devices, and other interventions, 2016-04, Vol.16 (2), p.119-127

2016

Volltextzugriff (PDF)

Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats

Drug metabolism and disposition, 2013-04, Vol.41 (4), p.906-915

2013

Volltextzugriff (PDF)

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

Platelets (Edinburgh), 2022-10, Vol.33 (7), p.969-978

2022

Volltextzugriff (PDF)

Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects

Clinical therapeutics, 2015-08, Vol.37 (8), p.1703-1712

2015

Volltextzugriff (PDF)

1 – 25 von 733

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(540)
Mit Volltextzugriff
(603)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(339)
Life Sciences & Biomedicine
(277)
Humans
(158)
Male
(131)
Animals
(105)
Biological And Medical Sciences
(102)
Female
(84)
Medical Sciences
(63)
Physical Sciences
(58)
Rats
(55)
Adult
(54)
Fundamental And Applied Biological Sciences. Psychology
(49)
Endocrinology & Metabolism
(46)
Pharmacology & Pharmacy
(45)
Middle Aged
(42)
Rats, Sprague-Dawley
(42)
Muscle, Skeletal - Metabolism
(38)
Physiology
(36)
Proteins
(30)
Mice
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review

Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

Assessing recovery of spectacled eiders using a Bayesian decision analysis

Apixaban metabolism and pharmacokinetics after oral administration to humans

In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies

Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects

Effects of Age and Sex on the Single-Dose Pharmacokinetics and Pharmacodynamics of Apixaban

Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects

Warming Arctic summers unlikely to increase productivity of shorebirds through renesting

Regional Gastrointestinal Absorption of Apixaban in Healthy Subjects

Characterization of efflux transporters involved in distribution and disposition of apixaban

Evaluation of Crushed Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics in Healthy Adults

Apixaban Pharmacokinetics and Pharmacodynamics in Subjects with Mild or Moderate Hepatic Impairment

Normothermic Regional Perfusion in Controlled Donation After Circulatory Death Liver Transplantation: A Systematic Review and Meta-Analysis

First-in-human study to assess the safety, pharmacokinetics, and pharmacodynamics of BMS-986141, a novel, reversible, small-molecule, PAR4 agonist in non-Japanese and Japanese healthy participants

First‐in‐human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS‐962212, a direct, reversible, small molecule factor XIa inhibitor in non‐Japanese and Japanese healthy subjects

Effect of Activated Charcoal on Apixaban Pharmacokinetics in Healthy Subjects

Apixaban Versus Warfarin for Mechanical Heart Valve Thromboprophylaxis in a Swine Aortic Heterotopic Valve Model

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

Investigating the enteroenteric recirculation of apixaban, a factor Xa inhibitor: administration of activated charcoal to bile duct-cannulated rats and dogs receiving an intravenous dose and use of drug transporter knockout rats

New oral protease-activated receptor 4 antagonist BMS-986120: tolerability, pharmacokinetics, pharmacodynamics, and gene variant effects in humans

Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects

Suchergebnisse filtern